Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis

Overview of attention for article published in CNS Drugs, June 2014

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 7 patents

Readers on

mendeley: 39 Mendeley

Summary Patents

So far, Altmetric has seen 7 patents that reference this research output.

Methods of treating inflammatory and autoimmune diseases with natalizumab

Grant US-11333670-B2

United States of America

Methods of treating inflammatory and autoimmune diseases with natalizumab

Grant US-11292845-B2

United States of America

Assay for JC virus antibodies

Grant US-11287423-B2

United States of America

Method of assessing risk of PML

Grant US-11280794-B2

United States of America

Method of assessing risk of PML

Grant US-10677803-B2

United States of America

Methods of treating inflammatory and autoimmune diseases with natalizumab

Grant US-10233245-B2

United States of America

Methods of treating inflammatory and autoimmune diseases with natalizumab

Grant US-9493567-B2

United States of America